Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers. The branded ...

Pfizer CEO Albert Bourla on Tuesday said ... in the U.S. It comes as drugmakers brace for Trump’s levies on pharmaceuticals imported into the country — his administration’s bid to boost ...

April 15, 2025 /PRNewswire/ -- Today, the Bladder Cancer Advocacy Network (BCAN) announced its partnerships with Ferring Pharmaceuticals and the Astellas/Pfizer Alliance as National Presenting ...